Sekido Y
Department of Clinical Preventive Medicine, Nagoya University Hospital.
Nihon Rinsho. 2000 May;58(5):1036-40.
Advances in lung cancer research have come from modern technology, allowing the establishment of lung cancer cell lines and experimental model systems, recombinant DNA technology, robust biological and biochemical functional assays in addition to classical methods such as immunohistochemistry. Such work indicates that the aberrant activation of protooncogenes and inactivation of tumor suppressor genes are fundamental processes for lung carcinogenesis. Further improvements such as DNA array technology will continue to unravel the genetic and epigenetic defects in a far more rapid and comprehensive way that was previously possible. This knowledge will lead to a genetic characterization of lung cancer cells and its specific subtypes, which will hopefully translate to new diagnostic and therapeutic gene based strategies. This review focuses on molecular biological techniques that have been used on lung cancer research and discusses future technological approaches.
肺癌研究的进展源于现代技术,这些技术使得肺癌细胞系和实验模型系统得以建立,重组DNA技术得以应用,除免疫组织化学等经典方法外,还开展了强大的生物学和生化功能测定。此类研究表明,原癌基因的异常激活和肿瘤抑制基因的失活是肺癌发生的基本过程。诸如DNA阵列技术等进一步的改进将继续以前所未有的速度和全面性揭示遗传和表观遗传缺陷。这些知识将促成对肺癌细胞及其特定亚型的基因特征描述,有望转化为基于基因的新诊断和治疗策略。本综述聚焦于已应用于肺癌研究的分子生物学技术,并探讨未来的技术方法。